FGFrankie G. Garcia

Frankie G. Garcia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Frankie G. Garcia has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Alex R. Bautista

    Center for Translational & Computational Neuroimmunology, Neuroimmunology Division, Department of Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, United States

    2 shared publications
  • Andrew A. Sproul

    Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University Irving Medical Center (CUIMC) New York New York USA

    2 shared publications
  • John F. Tuddenham

    Center for Translational & Computational Neuroimmunology, Neuroimmunology Division, Department of Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, United States

    2 shared publications
  • Natacha Comandante-Lou

    Columbia University Irving Medical Center

    2 shared publications
  • Peter Sims

    Department of Systems Biology, Columbia University Medical Center, New York, NY, USA

    2 shared publications
  • Philip Lawrence De Jager

    Center for Translational & Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, USA

    2 shared publications

Latest Publications

  • Open Access

    HDAC Inhibitors recapitulate Human Disease-Associated Microglia Signatures in vitro

    by Verena Haage, John F. Tuddenham, Alex Bautista, Charles C. White, Frankie Garcia, Ronak Patel, Natacha Comandante-Lou, Victoria Marshe, Rajesh Kumar Soni, Peter A. Sims, et al.

    Disease-associated microglia (DAM), initially described in mouse models of neurodegenerative diseases, have been classified into two related states; starting from a TREM2-independent DAM1 state to a TREM2 dependent state termed DAM2, with each state being characterized by the expression of specific marker genes 1 . Recently, single-cell (sc)RNA-Seq studies have reported the existence of DAMs in humans 2–6 ; however, whether DAMs play beneficial or detrimental roles in the context of neurodegeneration is still under debate 7,8 . Here, we present a pharmacological approach to mimic human DAM in vitro by exposing different human microglia models to selected histone deacetylase (HDAC) inhibitors. We also provide an initial functional characterization of our model system, showing a specific increase of amyloid beta phagocytosis along with a reduction of MCP-1 secretion. Additionally, we report an increase in MITF expression, a transcription factor previously described to drive expression towards the DAM phenotype. We further identify CADM1 , LIPA and SCIN as DAM- marker genes shared across various proposed DAM signatures and in our model systems. Overall, our strategy for targeted microglial polarization bears great potential to further explore human DAM function and biology.


  • Open Access

    A pharmacological toolkit for human microglia identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer’s disease

    by Verena Haage, John F. Tuddenham, Natacha Comandante-Lou, Alex Bautista, Anna Monzel, Rebecca Chiu, Masashi Fujita, Frankie G. Garcia, Prabesh Bhattarai, Ronak Patel, et al.

    : While efforts to identify microglial subtypes have recently accelerated, the relation of transcriptomically defined states to function has been largely limited to in silico annotations. Here, we characterize a set of pharmacological compounds that have been proposed to polarize human microglia towards two distinct states – one enriched for AD and MS genes and another characterized by increased expression of antigen presentation genes. Using different model systems including HMC3 cells, iPSC-derived microglia and cerebral organoids, we characterize the effect of these compounds in mimicking human microglial subtypes in vitro . We show that the Topoisomerase I inhibitor Camptothecin induces a CD74 high /MHC high microglial subtype which is specialized in amyloid beta phagocytosis. Camptothecin suppressed amyloid toxicity and restored microglia back to their homeostatic state in a zebrafish amyloid model. Our work provides avenues to recapitulate human microglial subtypes in vitro , enabling functional characterization and providing a foundation for modulating human microglia in vivo .